DR Congo Ebola outbreak 'spreads' to new province bordering Central African Republic - TRT Afrika
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
The ongoing Ebola outbreak in the Democratic Republic of Congo has spread to a new province bordering the Central African Republic, two health officials told Reuters News Agency on Thursday, posing a fresh challenge for authorities struggling to contain it. North Ubangi becomes the eighth province to be affected by the outbreak of the Bundibugyo species of Ebola, which was announced in mid-May and has become the second-largest Ebola outbreak on record, with more than 9,000 cases and more than 4,000 deaths confirmed. Two cases have been confirmed in North Ubangi, the officials said. They have not been officially announced by Congolese authorities. Ituri province remains the epicentre of the outbreak, though cases have increased recently in North Kivu province. Cases have also been confirmed in South Kivu, Tshopo, Haut-Uele, Bas-Uele and South Ubangi provinces. A health official in North Ubangi told Reuters on Thursday there had been a series of suspect deaths recently in a mining area in Wapinda health zone, close to the border with Bas-Uele, prompting samples to be analysed at a provincial laboratory and in Kinshasa.
This article is an excerpt. To read the full content, visit the original source. TRT Afrika
Related articles
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain - ScienceAlert
The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
0 comments
No comments yet. Be the first to share your thoughts!